Sugi Predict

Sugi Predict / Compounds / SCHEMBL29376701

SCHEMBL29376701

SCHEMBL29376701

CCCC(NC(=O)/C(C#N)=C/c1nc(Cl)ccc1Cl)c1ccc(OCCN2CCOCC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP9X Q93008 10/20 1.00
▸ USP24 Q9UPU5 1/20 1.00
▸ KMT2A Q03164 4/20 0.50
▸ CACNA1B Q00975 1/20 0.47
▸ APBA1 Q02410 1/20 0.47
▸ GAA P10253 2/20 0.46
▸ NPC1 O15118 3/20 0.41
▸ UCHL1 P09936 1/20 0.41
▸ USP5 P45974 1/20 0.41
▸ BRAF P15056 1/20 0.40
▸ MAPK14 Q16539 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ACACB O00763 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16647263 1.00 USP9X (1.00) USP9XUSP24KMT2ACACNA1BAPBA1
SCHEMBL17986430 1.00 USP9X (1.00) USP9XUSP24KMT2ACACNA1BAPBA1
SCHEMBL16647252 0.93 USP9X (0.88) USP9XUSP24KMT2ACACNA1BAPBA1
SCHEMBL18017557 0.93 USP9X (0.86) USP9XUSP24KMT2ACACNA1BAPBA1
SCHEMBL18017555 0.93 USP9X (0.86) USP9XUSP24KMT2ACACNA1BAPBA1
SCHEMBL16647236 0.90 USP9X (0.82) USP9XUSP24KMT2ACACNA1BAPBA1
SCHEMBL23171163 0.87 USP9X (0.76) USP9XUSP24KMT2ACACNA1BAPBA1
SCHEMBL18017556 0.86 USP9X (0.75) USP9XUSP24KMT2ACACNA1BAPBA1
SCHEMBL18017567 0.85 USP9X (0.74) USP9XUSP24KMT2AUCHL1USP5
SCHEMBL18017565 0.85 USP9X (0.73) USP9XUSP24KMT2AGAAUCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118787743-A Application of TRIP13-EZH2 signal pathway inhibitor in preparation of medicines for treating multiple myeloma 上海市东方医院（同济大学附属东方医院） 2024-10-18 — — CN claimed
US-20230123585-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS UNIV CHICAGO (US) 2023-04-20 — — US claimed
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2025-05-08 — — US disclosed
US-12168640-B2 USP9X inhibitors ProDeg, LLC (US) 2024-12-17 — — US disclosed
EP-4455136-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE Scinnohub Pharmaceutical Co., Ltd. (CN) 2024-10-30 — — EP disclosed
CN-118787752-A Pharmaceutical composition and application thereof in preparation of medicines for treating multiple myeloma 上海市东方医院（同济大学附属东方医院） 2024-10-18 — — CN disclosed
CN-118787743-A Application of TRIP13-EZH2 signal pathway inhibitor in preparation of medicines for treating multiple myeloma 上海市东方医院（同济大学附属东方医院） 2024-10-18 — — CN disclosed
EP-4433462-A1 USP9X INHIBITORS Prodeg, LLC (US) 2024-09-25 — — EP disclosed
US-20240294467-A1 USP9X Inhibitors ProDeg, LLC 2024-09-05 — — US disclosed
CN-118510768-A Diazasulfinyl structure-containing compounds and their use in medicine 赛诺哈勃药业（成都）有限公司 2024-08-16 — — CN disclosed
CN-116785287-A Application of deubiquitinase inhibitor in preparation of drugs for inhibiting replication of hepatitis B virus by enhancing interferon 重庆医科大学 2023-09-22 — — CN disclosed
US-20230227418-A1 USP9X INHIBITORS ProDeg, LLC 2023-07-20 — — US disclosed
US-11691945-B2 USP9X inhibitors ProDeg, LLC (US) 2023-07-04 — — US disclosed
WO-2023116774-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE 赛诺哈勃药业（成都）有限公司 2023-06-29 — — WO disclosed
CN-116178302-A CD47 protein ubiquitination modified agonist and application thereof 武汉大学中南医院 2023-05-30 — — CN disclosed
WO-2023091464-A1 USP9X INHIBITORS ProDeg, LLC (US) 2023-05-25 — — WO disclosed
WO-2023089601-A2 USP9X INHIBITORS ProDeg, LLC (US) 2023-05-25 — — WO disclosed
US-20230150925-A1 USP9X INHIBITORS ProDeg, LLC 2023-05-18 — — US disclosed
US-20230123585-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS UNIV CHICAGO (US) 2023-04-20 — — US disclosed
US-20220041597-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2022-02-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691945-B2 USP9X inhibitors USP9X, USP19, USP39 USP9X 1/4885USP24 23/4885KMT2A 531/4885
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE BCL9, USP9X, BCL9L USP9X 2/4885USP24 117/4885KMT2A 646/4885
US-20240294467-A1 USP9X Inhibitors USP9X, USP19, USP39 USP9X 1/4885USP24 23/4885KMT2A 531/4885
US-20230150925-A1 USP9X INHIBITORS USP9X, USP19, USP39 USP9X 1/4885USP24 23/4885KMT2A 531/4885
US-12168640-B2 USP9X inhibitors USP9X, USP19, USP39 USP9X 1/4885USP24 23/4885KMT2A 531/4885
US-20220041597-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X MCL1, HSPA9, USP10 USP9X 6/4885USP24 60/4885KMT2A 663/4885
US-20230227418-A1 USP9X INHIBITORS USP9X, USP19, USP39 USP9X 1/4885USP24 23/4885KMT2A 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.